Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

(2016) A. C. Phillips et al.   MOLECULAR CANCER THERAPEUTICS

Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis

(2015) J.-R. Chen et al.   ACTA NEUROLOGICA SCANDINAVICA

Molecular and Genomic Alterations in Glioblastoma Multiforme

(2015) Ines Crespo et al.   AMERICAN JOURNAL OF PATHOLOGY

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL

(2015) W. Wick et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited

(2015) Nicola Montano et al.   NEOPLASIA

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

(2014) Nizar M. Tannir et al.   INVESTIGATIONAL NEW DRUGS

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

(2014) Parvin F. Peddi et al.   Therapeutic Advances in Medical Oncology

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

(2013) Hui K. Gan et al.   FEBS Journal

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

(2013) Michael Weller et al.   INTERNATIONAL JOURNAL OF CANCER

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

(2013) Tae H. Han et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Abstract 2924: Constitutively active androgen receptor splice variants function independently of full-length androgen receptor in a cell-based model of castrate-resistant prostate cancer

(2012) Peter E. Lonergan et al.   CANCER RESEARCH

Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas

(2012) Li-li Zhao et al.   HISTOPATHOLOGY

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

(2012) Arnab Chakravarti et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Brentuximab vedotin

(2012) Anas Younes et al.   NATURE REVIEWS DRUG DISCOVERY

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074

(2010) Joon H. Uhm et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma

(2010) Jing Li et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

(2009) B. Neyns et al.   ANNALS OF ONCOLOGY

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples

(2008) K. Yoshimoto et al.   CLINICAL CANCER RESEARCH

Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma

(2008) Ilse Vlassenbroeck et al.   JOURNAL OF MOLECULAR DIAGNOSTICS